Teijin America, Inc.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis (NCT05437419) | Teijin America, Inc. | 2022-08-10 |
| Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria (NCT03449199) | Teijin America, Inc. | 2018-04-10 |
Track Teijin America, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.